ConsiGma®
An indispensable part of the ConsiGma portfolio, the Conductor control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line.

GEA’s Conductor is the highly advanced, SCADA-based heart of the control system architecture that brings all the smart and robust ConsiGma® processes and technological solutions together in one easily controlled environment.
It interfaces with the automation layers of the individual ConsiGma® modules, which are part of the lines, PAT instruments (if present) and PAT management systems, Advanced Process Control systems such as PharmaMV® (Perceptive Engineering), Data historian and MES solutions, all depending on the customer IT landscape.
Read more about how GEA and its partners are implementing this technology to lead the way toward smaller, more flexible, continuous processing technologies that are transforming the future of pharmaceutical development and manufacturing.

A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.

The ConsiGma® Film Coater is based on the GEA high-performance tablet coating technology that gently and accurately deposits controlled amounts of coating materials onto tablet cores — even if they are hygroscopic or friable.

The ConsiGma® 1 offers standalone continuous twin-screw granulation and drying for small-scale R&D operations. It allows users to develop the process and achieve high granule quality on a compact unit.

Based on proven continuous twin-screw granulation technology, the ConsiGma® GD modules enable the production of higher quality granules under better control, even in a bin-2-bin set-up.
GEA centrifuges enable wastewater reuse, resource recovery, and water security by turning biosolids into value in a world facing growing water scarcity.
Last year was not a year of hyped-up headlines for alternative proteins. Perhaps that is precisely why it was an important year for food biotech, the biotechnology behind everyday foods and ingredients. While the sector worked through a difficult funding environment, approvals were still granted, pilot lines set up and new platforms tested in the background. In short: headlines are turning into infrastructure. Frederieke Reiners heads GEA’s New Food business. She and her team work at the intersection of biotechnology and industrial food production. In this interview, she takes us on a world tour of food biotech in seven questions.
Pets are family – and owners expect premium, transparent and sustainable nutrition. Freeze-drying, powered by GEA technology, helps pet food makers deliver.